Substance P Antagonists as a Therapeutic Approach to Improving Outcome Following Traumatic Brain Injury

Neurotherapeutics

Volumn 7, Issue 1, 2010, Pages 74-80

  Vink, Robert ^a   van den Heuvel, Corinna ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

edema; inflammation; Neurotrauma; substance P; tachykinins

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; CALCITONIN GENE RELATED PEPTIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ A; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TACHYKININ;

ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN ISCHEMIA; CELL DEATH; HUMAN; INTRACRANIAL PRESSURE; LEARNING; MEMORY; MIGRAINE; MOOD; NERVE CELL; NEUROGENIC INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; SEIZURE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; VOMITING;

ANIMALS; BRAIN INJURIES; HUMANS; KININS; MODELS, BIOLOGICAL; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TREATMENT OUTCOME;

EID: 72949094390     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.10.018     Document Type: Article

References (70)

1. Tagliaferri F., Compagnone C., Korsic M., Servadei F., and Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 148 (2006) 255-268
2. Blumbergs P.C., Reilly P.L., and Vink R. Trauma. In: Love S., Louis D.N., and Ellison D.W. (Eds). Greenfield's neuropathology. 8th ed. (2008), Hodder Arnold, London 733-832
3. McIntosh T.K., Smith D.H., Meaney D.F., Kotapka M.J., Gennarelli T.A., and Graham D.I. Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest 74 (1996) 315-342
4. Feickert H.J., Drommer S., and Heyer R. Severe head injury in children: impact of risk factors on outcome. J Trauma 47 (1999) 33-38
5. Marmarou A., Fatouros P.P., Barzó P., et al. Contribution of edema and cerebral blood volume to traumatic brain swelling in head-injured patients. J Neurosurg 93 (2000) 183-193
6. Brain Trauma Foundation; American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care. Initial management. J Neurotrauma 17 (2000) 463-469
7. Nimmo A.J., Cernak I., Heath D.L., Hu X., Bennett C.J., and Vink R. Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats. Neuropeptides 38 (2004) 40-47
8. Donkin J.J., Nimmo A.J., Cernak I., Blumbergs P.C., and Vink R. A critical role for substance P in the development of traumatic brain edema. J Cereb Blood Flow Metab 29 (2009) 1388-1398
9. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., and Erspamer V. The tachykinin peptide family. Pharmacol Rev 54 (2002) 285-322
10. von Euler U.S., and Gaddum J.H. An unidentified depressor substance in certain tissue extracts. J Physiol 72 (1931) 74-87
11. Lembeck F. Central transmission of afferent impulses: III. Incidence and significance of the substance P in the dorsal roots of the spinal cord [In German]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 219 (1953) 197-213
12. Otsuka M., and Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73 (1993) 229-308
13. 2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J Neurotrauma 19 (2002) 953-964
14. 2 receptor antagonist, decreases ex vivo brain tissue prostaglandin E2 synthesis after closed head trauma in rats. Resuscitation 56 (2003) 207-213
15. Marmarou A., Nichols J., Burgess J., et al. Effects of the bradykinin antagonist Bradycor (deltibant, CP-1027) in severe traumatic brain injury: results of a multi-center, randomized, placebo-controlled trial. J Neurotrauma 16 (1999) 431-444
16. 2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett 454 (2009) 115-117
17. Rodi D., Couture R., Ongali B., and Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 11 (2005) 1313-1326
18. 2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury. Free Radic Biol Med 41 (2006) 1304-1314
19. Noda M., Kariura Y., Pannasch U., et al. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J Neurochem 101 (2007) 397-410
20. Bayliss W.M. On the origin from the spinal cord of the vaso-dilator fibres of the hind-limb, and on the nature of these fibres. J Physiol 26 (1901) 173-209
21. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16 (2002) 622-653
22. Geppetti P., Bertrand C., Ricciardolo F.L., and Nadel J.A. New aspects on the role of kinins in neurogenic inflammation. Can J Physiol Pharmacol 73 (1995) 843-847
23. Ferrari M.D. Migraine. Lancet 351 (1998) 1043-1051
24. Szallasi A., and Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51 (1999) 159-212
25. Caterina M.J., Schumacher M.A., Tominaga M., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
26. Szolcsányi J., and Mózsik G. Effects of capsaicin on the development of gastric mucosal damage by different necrotizing agents and of gastric cytoprotection by PGI2 atropine and cimetidine on rats. Acta Physiol Hung 64 (1984) 287-291
27. Marmarou A. A review of progress in understanding the pathophysiology and treatment of brain edema. Neurosurg Focus 22 5 (2007) E1
28. Nag S., Manias J.L., and Stewart D.J. Pathology and new players in the pathogenesis of brain edema. Acta Neuropathol 118 (2009) 197-217
29. Habgood M.D., Bye N., Dziegielewska K.M., et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci 25 (2007) 231-238
30. Marmarou A., Portella G., Barzo P., et al. Distinguishing between cellular and vasogenic edema in head injured patients with focal lesions using magnetic resonance imaging. Acta Neurochir Suppl (Wien) 76 (2000) 349-351
31. Beaumont A., Marmarou A., Hayasaki K., et al. The permissive nature of blood brain barrier (BBB) opening in edema formation following traumatic brain injury. Acta Neurochir Suppl (Wien) 76 (2000) 125-129
32. Arvin B., Neville L.F., Barone F.C., and Feuerstein G.Z. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 20 (1996) 445-452
33. Morganti-Kossmann M.C., Rancan M., Stahel P.F., and Kossmann T. Inflammatory response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 8 (2002) 101-105
34. Saria A. Substance P in sensory nerve fibres contributes to the development of oedema in the rat hind paw after thermal injury. Br J Pharmacol 82 (1984) 217-222
35. Yonehara N., Shibutani T., and Inoki R. Contribution of substance P to heat-induced edema in rat paw. J Pharmacol Exp Ther 242 (1987) 1071-1076
36. De A.K., and Ghosh J.J. Inflammatory responses induced by substance P in rat paw. Indian J Exp Biol 28 (1990) 946-948
37. Donkin J.J., Cernak I., Rodgers K.M., and Vink R. Mild concussive head injury results in increased brain substance P immunoreactivity. 7th International Neurotrauma Symposium (2004), Medimond International Proceedings, Bologna 75-78
38. Zacest A.C., Vink R., Manavis J., Sarvestani G.T., and Blumbergs P.C. Substance P immunoreactivity increases following human traumatic brain injury. Acta Neurochir Suppl (Wien) 106 (2009) 211-216
39. Brain S.D., and Williams T.J. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol 86 (1985) 855-860
40. Hökfelt T., Pernow B., and Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med 249 (2001) 27-40
41. Malcangio M., Ramer M.S., Jones M.G., and McMahon S.B. Abnormal substance P release from the spinal cord following injury to primary sensory neurons. Eur J Neurosci 12 (2000) 397-399
42. Sharma H.S., Nyberg F., Olsson Y., and Dey P.K. Alteration of substance P after trauma to the spinal cord: an experimental study in the rat. Neuroscience 38 (1990) 205-212
43. Annunziata P., Cioni C., Santonini R., and Paccagnini E. Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J Neuroimmunol 131 (2002) 41-49
44. Stumm R., Culmsee C., Schafer M.K., Krieglstein J., and Weihe E. Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to GABAergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium. J Neurosci 21 (2001) 798-811
45. Turner R.J., Blumbergs P.C., Sims N.R., Helps S.C., Rodgers K.M., and Vink R. Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl (Wien) 96 (2006) 263-266
46. Bruno G., Tega F., Bruno A., et al. The role of substance P in cerebral ischemia. Int J Immunopathol Pharmacol 16 (2003) 67-72
47. Mantyh P.W., Johnson D.J., Boehmer C.G., et al. Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. Proc Natl Acad Sci U S A 86 (1989) 5193-5197
48. Lin R.C. Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 7 (1995) 310-312
49. Castro-Obregón S., Rao R.V., del Rio G., et al. Alternative, nonapoptotic programmed cell death: mediation by arrestin-2, ERK2 and Nur77. J Biol Chem 279 (2004) 17543-17553
50. Alvaro G., and Di Fabio R. Neurokinin 1 receptor antagonists: current prospects. Curr Opin Drug Discov Devel 10 (2007) 613-621
51. Liu H., Mazarati A.M., Katsumori H., Sankar R., and Wasterlain C.G. Substance P is expressed in hippocampal principal neurons during status epilepticus and plays a critical role in the maintenance of status epilepticus. Proc Natl Acad Sci U S A 96 (1999) 5286-5291
52. Leban J., Rackur G., Yamaguchi I., et al. Synthesis of substance P analogs and agonistic and antagonistic activities. Acta Chem Scand B 33 (1979) 664-668
53. Folkers K., Hörig J., Rosell S., and Björkroth U. Chemical design of antagonists of substance P. Acta Physiol Scand 111 (1981) 505-506
54. Engberg G., Svensson T.H., Rosell S., and Folkers K. A synthetic peptide as an antagonist of substance P. Nature 293 (1981) 222-223
55. Snider R.M., Longo K.P., Drozda S.E., Lowe III J.A., and Leeman S.E. Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci U S A 88 (1991) 10042-10044
56. MacLeod A.M., Cascieri M.A., Merchant K.J., et al. Synthesis and biological evaluation of NK1 antagonists derived from l-tryptophan. J Med Chem 38 (1995) 934-941
57. Rupniak N.M., and Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 20 (1999) 485-490
58. Santarelli L., Gobbi G., Debs P.C., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci U S A 98 (2001) 1912-1917
59. Ranga K., and Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 63 Suppl 11 (2002) 25-29
60. Vink R., Donkin J.J., Cruz M.I., Nimmo A.J., and Cernak I. A substance P antagonist increases brain intracellular free magnesium concentration after diffuse traumatic brain injury in rats. J Am Coll Nutr 23 (2004) 538S-540S
61. Vink R. Nuclear magnetic resonance characterization of secondary mechanisms following traumatic brain injury. Mol Chem Neuropathol 18 (1993) 279-297
62. Vink R., O'Connor C.A., Nimmo A.J., and Heath D.L. Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats. Neurosci Lett 336 (2003) 41-44
63. Vink R., and Nimmo A.J. Multifunctional drugs for head injury. Neurotherapeutics 6 (2009) 28-42
64. Yu Z., Cheng G., Huang X., Li K., and Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport 8 (1997) 2117-2119
65. Turner R., and Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Drug News Perspect 20 (2007) 221-226
66. Souza D.G., Mendonça V.A., de A Castro M.S., Poole S., and Teixeira M.M. Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat. Br J Pharmacol 135 (2002) 303-312
67. Kramer J.H., Phillips T.M., and Weglicki W.B. Magnesium deficiency enhanced post-ischemic myocardial injury is reduced by substance P receptor blockade. J Cardiol 29 (1997) 97-110
68. Heath D.L., and Vink R. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration. Brain Res 738 (1996) 150-153
69. Campos M.M., and Calixto J.B. Neurokinin mediation of edema and inflammation. Neuropeptides 34 (2000) 314-322
70. Kashiba H., Ueda Y., and Senba E. Systemic capsaicin in the adult rat differentially affects gene expression for neuropeptides and neurotrophin receptors in primary sensory neurons. Neuroscience 76 (1997) 299-312